Cargando…

Multimodality imaging using proton magnetic resonance spectroscopic imaging and (18)F-fluorodeoxyglucose-positron emission tomography in local prostate cancer

AIM: To assess the relationship using multimodality imaging between intermediary citrate/choline metabolism as seen on proton magnetic resonance spectroscopic imaging ((1)H-MRSI) and glycolysis as observed on (18)F-fluorodeoxyglucose positron emission tomography/computed tomography ((18)F-FDG-PET/CT...

Descripción completa

Detalles Bibliográficos
Autores principales: Shukla-Dave, Amita, Wassberg, Cecilia, Pucar, Darko, Schöder, Heiko, Goldman, Debra A, Mazaheri, Yousef, Reuter, Victor E, Eastham, James, Scardino, Peter T, Hricak, Hedvig
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Baishideng Publishing Group Inc 2017
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5368629/
https://www.ncbi.nlm.nih.gov/pubmed/28396727
http://dx.doi.org/10.4329/wjr.v9.i3.134
_version_ 1782517962909941760
author Shukla-Dave, Amita
Wassberg, Cecilia
Pucar, Darko
Schöder, Heiko
Goldman, Debra A
Mazaheri, Yousef
Reuter, Victor E
Eastham, James
Scardino, Peter T
Hricak, Hedvig
author_facet Shukla-Dave, Amita
Wassberg, Cecilia
Pucar, Darko
Schöder, Heiko
Goldman, Debra A
Mazaheri, Yousef
Reuter, Victor E
Eastham, James
Scardino, Peter T
Hricak, Hedvig
author_sort Shukla-Dave, Amita
collection PubMed
description AIM: To assess the relationship using multimodality imaging between intermediary citrate/choline metabolism as seen on proton magnetic resonance spectroscopic imaging ((1)H-MRSI) and glycolysis as observed on (18)F-fluorodeoxyglucose positron emission tomography/computed tomography ((18)F-FDG-PET/CT) in prostate cancer (PCa) patients. METHODS: The study included 22 patients with local PCa who were referred for endorectal magnetic resonance imaging/(1)H-MRSI (April 2002 to July 2007) and (18)F-FDG-PET/CT and then underwent prostatectomy as primary or salvage treatment. Whole-mount step-section pathology was used as the standard of reference. We assessed the relationships between PET parameters [standardized uptake value (SUVmax and SUVmean)] and MRSI parameters [choline + creatine/citrate (CC/Cmax and CC/Cmean) and total number of suspicious voxels] using spearman’s rank correlation, and the relationships of PET and (1)H-MRSI index lesion parameters to surgical Gleason score. RESULTS: Abnormal intermediary metabolism on (1)H-MRSI was present in 21/22 patients, while abnormal glycolysis on (18)F-FDG-PET/CT was detected in only 3/22 patients. Specifically, index tumor localization rates were 0.95 (95%CI: 0.77-1.00) for (1)H-MRSI and 0.14 (95%CI: 0.03-0.35) for (18)F-FDG-PET/CT. Spearman rank correlations indicated little relationship (ρ = -0.36-0.28) between (1)H-MRSI parameters and (18)F-FDG-PET/CT parameters. Both the total number of suspicious voxels (ρ = 0.55, P = 0.0099) and the SUVmax (ρ = 0.46, P = 0.0366) correlated weakly with the Gleason score. No significant relationship was found between the CC/Cmax, CC/Cmean or SUVmean and the Gleason score (P = 0.15-0.79). CONCLUSION: The concentration of intermediary metabolites detected by (1)H MRSI and glycolytic flux measured (18)F-FDG PET show little correlation. Furthermore, only few tumors were FDG avid on PET, possibly because increased glycolysis represents a late and rather ominous event in the progression of PCa.
format Online
Article
Text
id pubmed-5368629
institution National Center for Biotechnology Information
language English
publishDate 2017
publisher Baishideng Publishing Group Inc
record_format MEDLINE/PubMed
spelling pubmed-53686292017-04-10 Multimodality imaging using proton magnetic resonance spectroscopic imaging and (18)F-fluorodeoxyglucose-positron emission tomography in local prostate cancer Shukla-Dave, Amita Wassberg, Cecilia Pucar, Darko Schöder, Heiko Goldman, Debra A Mazaheri, Yousef Reuter, Victor E Eastham, James Scardino, Peter T Hricak, Hedvig World J Radiol Observational Study AIM: To assess the relationship using multimodality imaging between intermediary citrate/choline metabolism as seen on proton magnetic resonance spectroscopic imaging ((1)H-MRSI) and glycolysis as observed on (18)F-fluorodeoxyglucose positron emission tomography/computed tomography ((18)F-FDG-PET/CT) in prostate cancer (PCa) patients. METHODS: The study included 22 patients with local PCa who were referred for endorectal magnetic resonance imaging/(1)H-MRSI (April 2002 to July 2007) and (18)F-FDG-PET/CT and then underwent prostatectomy as primary or salvage treatment. Whole-mount step-section pathology was used as the standard of reference. We assessed the relationships between PET parameters [standardized uptake value (SUVmax and SUVmean)] and MRSI parameters [choline + creatine/citrate (CC/Cmax and CC/Cmean) and total number of suspicious voxels] using spearman’s rank correlation, and the relationships of PET and (1)H-MRSI index lesion parameters to surgical Gleason score. RESULTS: Abnormal intermediary metabolism on (1)H-MRSI was present in 21/22 patients, while abnormal glycolysis on (18)F-FDG-PET/CT was detected in only 3/22 patients. Specifically, index tumor localization rates were 0.95 (95%CI: 0.77-1.00) for (1)H-MRSI and 0.14 (95%CI: 0.03-0.35) for (18)F-FDG-PET/CT. Spearman rank correlations indicated little relationship (ρ = -0.36-0.28) between (1)H-MRSI parameters and (18)F-FDG-PET/CT parameters. Both the total number of suspicious voxels (ρ = 0.55, P = 0.0099) and the SUVmax (ρ = 0.46, P = 0.0366) correlated weakly with the Gleason score. No significant relationship was found between the CC/Cmax, CC/Cmean or SUVmean and the Gleason score (P = 0.15-0.79). CONCLUSION: The concentration of intermediary metabolites detected by (1)H MRSI and glycolytic flux measured (18)F-FDG PET show little correlation. Furthermore, only few tumors were FDG avid on PET, possibly because increased glycolysis represents a late and rather ominous event in the progression of PCa. Baishideng Publishing Group Inc 2017-03-28 2017-03-28 /pmc/articles/PMC5368629/ /pubmed/28396727 http://dx.doi.org/10.4329/wjr.v9.i3.134 Text en ©The Author(s) 2017. Published by Baishideng Publishing Group Inc. All rights reserved. http://creativecommons.org/licenses/by-nc/4.0/ This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial.
spellingShingle Observational Study
Shukla-Dave, Amita
Wassberg, Cecilia
Pucar, Darko
Schöder, Heiko
Goldman, Debra A
Mazaheri, Yousef
Reuter, Victor E
Eastham, James
Scardino, Peter T
Hricak, Hedvig
Multimodality imaging using proton magnetic resonance spectroscopic imaging and (18)F-fluorodeoxyglucose-positron emission tomography in local prostate cancer
title Multimodality imaging using proton magnetic resonance spectroscopic imaging and (18)F-fluorodeoxyglucose-positron emission tomography in local prostate cancer
title_full Multimodality imaging using proton magnetic resonance spectroscopic imaging and (18)F-fluorodeoxyglucose-positron emission tomography in local prostate cancer
title_fullStr Multimodality imaging using proton magnetic resonance spectroscopic imaging and (18)F-fluorodeoxyglucose-positron emission tomography in local prostate cancer
title_full_unstemmed Multimodality imaging using proton magnetic resonance spectroscopic imaging and (18)F-fluorodeoxyglucose-positron emission tomography in local prostate cancer
title_short Multimodality imaging using proton magnetic resonance spectroscopic imaging and (18)F-fluorodeoxyglucose-positron emission tomography in local prostate cancer
title_sort multimodality imaging using proton magnetic resonance spectroscopic imaging and (18)f-fluorodeoxyglucose-positron emission tomography in local prostate cancer
topic Observational Study
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5368629/
https://www.ncbi.nlm.nih.gov/pubmed/28396727
http://dx.doi.org/10.4329/wjr.v9.i3.134
work_keys_str_mv AT shukladaveamita multimodalityimagingusingprotonmagneticresonancespectroscopicimagingand18ffluorodeoxyglucosepositronemissiontomographyinlocalprostatecancer
AT wassbergcecilia multimodalityimagingusingprotonmagneticresonancespectroscopicimagingand18ffluorodeoxyglucosepositronemissiontomographyinlocalprostatecancer
AT pucardarko multimodalityimagingusingprotonmagneticresonancespectroscopicimagingand18ffluorodeoxyglucosepositronemissiontomographyinlocalprostatecancer
AT schoderheiko multimodalityimagingusingprotonmagneticresonancespectroscopicimagingand18ffluorodeoxyglucosepositronemissiontomographyinlocalprostatecancer
AT goldmandebraa multimodalityimagingusingprotonmagneticresonancespectroscopicimagingand18ffluorodeoxyglucosepositronemissiontomographyinlocalprostatecancer
AT mazaheriyousef multimodalityimagingusingprotonmagneticresonancespectroscopicimagingand18ffluorodeoxyglucosepositronemissiontomographyinlocalprostatecancer
AT reutervictore multimodalityimagingusingprotonmagneticresonancespectroscopicimagingand18ffluorodeoxyglucosepositronemissiontomographyinlocalprostatecancer
AT easthamjames multimodalityimagingusingprotonmagneticresonancespectroscopicimagingand18ffluorodeoxyglucosepositronemissiontomographyinlocalprostatecancer
AT scardinopetert multimodalityimagingusingprotonmagneticresonancespectroscopicimagingand18ffluorodeoxyglucosepositronemissiontomographyinlocalprostatecancer
AT hricakhedvig multimodalityimagingusingprotonmagneticresonancespectroscopicimagingand18ffluorodeoxyglucosepositronemissiontomographyinlocalprostatecancer